 |
|
Anthrax vaccine produces immunity with nanoparticles, not needles
August 17, 2007Easy-to-use nasal emulsion could protect after bioterror attack
ANN ARBOR, Mich. - A vaccine against anthrax that is more effective and easier to administer than the present vaccine has proved highly effective in tests in mice and guinea pigs, report University of Michigan Medical School scientists in the August issue of Infection and Immunity.
The scientists were able to trigger a strong immune response by treating the inside of the animals' noses with a "nanoemulsion" - a suspension of water, soybean oil, alcohol and surfactant emulsified to create droplets of only 200 to 300 nanometers in size. It would take about 265 of the droplets lined up side by side to equal the width of a human hair.
The oil particles are small enough to ferry a key anthrax protein inside the nasal membranes, allowing immune-system cells to react to the protein and initiate a protective immune response. That primes the immune system to promptly fight off infection when it encounters the whole microbe.
Besides eliminating the need for needles, the nanoemulsion anthrax vaccine has another advantage, the researchers say: It is easy to store and use in places where refrigeration is not available.
An effective and easy-to-administer vaccine would be a valuable tool for health authorities dealing with any future attack in which a terrorist might spread anthrax microbes. The researchers say a nasal nanoemulsion-based anthrax vaccine, if it proves effective in humans, could be given easily to people even after they are exposed in an anthrax attack, along with antibiotics. With some diseases, vaccines given after exposure are used to boost the speed of the immune response.
"Anthrax spores can remain in the environment or even in the lungs of exposed individuals for some time. Nasal vaccination could be given to build up immunity after anthrax exposure and improve the outcome of other treatments," says Anna Bielinska, Ph.D., the paper's lead author and a scientist at the Michigan Nanotechnology Institute for Medicine and Biological Sciences at the U-M. She is also an assistant research professor in the Allergy Division of Internal Medicine at the U-M Medical School.
In the 2001 attack in which anthrax spores were mailed to members of Congress and reporters, some anthrax-exposed individuals were given antibiotics but not the existing anthrax vaccine, because it requires six injections over a period of six months and may cause adverse reactions.
In the new study, the U-M team combined the nanoemulsion and a recombinant protein of Bacillus anthracis to make the vaccine, which they gave first to mice in either one or two applications. They found the animals developed several types of effective immune response. The vaccine produced both systemic and cellular immunity, meaning that the body produces antibodies and primes specific cells throughout the body to fend off anthrax infection. The vaccine also induced immunity on the mucous membranes of the nose and lungs, where inhaled anthrax spores enter the body and start a process that can cause illness and death.
"We saw protective immunity in the animals after only two administrations rather than six," says James R. Baker, Jr., M.D., director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences and the senior author of the study. He is the Ruth Dow Doan Professor in the Department of Internal Medicine and chief of the Division of Allergy and Clinical Immunology in the U-M Medical School.
After administering the vaccine, the researchers challenged the immune systems of immunized guinea pigs with injections of 1,000 times the lethal dose of Bacillus anthracis spores. All the animals survived, whereas none of the control animals did.
When the researchers delivered large doses of Bacillus anthracis spores directly into the animals' nasal tissue, they found that 40 percent to 70 percent of the immunized animals survived.
Because of the biosafety restrictions on the use of anthrax, these challenge experiments were done at the Batelle Memorial Institute and the University of Texas Medical Branch, which have labs federally approved for handling the pathogen.
The experiments so far have shown that the vaccine had no significant side effects and produced effective immunity for at least six months. The Michigan Nanotechnology Institute will seek funding to learn if the vaccine can produce immunity in primates as it does in rodents. Safety studies in humans are also in the early planning stage.
Scientists at the U-M earlier developed the nanoemulsion technique, which has been used to develop treatments for herpes and toenail fungus. The Michigan Nanotechnology Institute for Medicine and Biological Sciences was established at U-M in 2005 to develop and market medical and biological applications of nanotechnology. Patent applications for the nanoemulsion technology have been filed and exclusively licensed to NanoBio Corporation, an Ann Arbor, Mich.-based biotechnology company in which Baker has a financial interest.
University of Michigan Health System
The oil particles are small enough to ferry a key anthrax protein inside the nasal membranes, allowing immune-system cells to react to the protein and initiate a protective immune response. That primes the immune system to promptly fight off infection when it encounters the whole microbe.
Besides eliminating the need for needles, the nanoemulsion anthrax vaccine has another advantage, the researchers say: It is easy to store and use in places where refrigeration is not available.
An effective and easy-to-administer vaccine would be a valuable tool for health authorities dealing with any future attack in which a terrorist might spread anthrax microbes. The researchers say a nasal nanoemulsion-based anthrax vaccine, if it proves effective in humans, could be given easily to people even after they are exposed in an anthrax attack, along with antibiotics. With some diseases, vaccines given after exposure are used to boost the speed of the immune response.
"Anthrax spores can remain in the environment or even in the lungs of exposed individuals for some time. Nasal vaccination could be given to build up immunity after anthrax exposure and improve the outcome of other treatments," says Anna Bielinska, Ph.D., the paper's lead author and a scientist at the Michigan Nanotechnology Institute for Medicine and Biological Sciences at the U-M. She is also an assistant research professor in the Allergy Division of Internal Medicine at the U-M Medical School.
In the 2001 attack in which anthrax spores were mailed to members of Congress and reporters, some anthrax-exposed individuals were given antibiotics but not the existing anthrax vaccine, because it requires six injections over a period of six months and may cause adverse reactions.
In the new study, the U-M team combined the nanoemulsion and a recombinant protein of Bacillus anthracis to make the vaccine, which they gave first to mice in either one or two applications. They found the animals developed several types of effective immune response. The vaccine produced both systemic and cellular immunity, meaning that the body produces antibodies and primes specific cells throughout the body to fend off anthrax infection. The vaccine also induced immunity on the mucous membranes of the nose and lungs, where inhaled anthrax spores enter the body and start a process that can cause illness and death.
"We saw protective immunity in the animals after only two administrations rather than six," says James R. Baker, Jr., M.D., director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences and the senior author of the study. He is the Ruth Dow Doan Professor in the Department of Internal Medicine and chief of the Division of Allergy and Clinical Immunology in the U-M Medical School.
After administering the vaccine, the researchers challenged the immune systems of immunized guinea pigs with injections of 1,000 times the lethal dose of Bacillus anthracis spores. All the animals survived, whereas none of the control animals did.
When the researchers delivered large doses of Bacillus anthracis spores directly into the animals' nasal tissue, they found that 40 percent to 70 percent of the immunized animals survived.
Because of the biosafety restrictions on the use of anthrax, these challenge experiments were done at the Batelle Memorial Institute and the University of Texas Medical Branch, which have labs federally approved for handling the pathogen.
The experiments so far have shown that the vaccine had no significant side effects and produced effective immunity for at least six months. The Michigan Nanotechnology Institute will seek funding to learn if the vaccine can produce immunity in primates as it does in rodents. Safety studies in humans are also in the early planning stage.
Scientists at the U-M earlier developed the nanoemulsion technique, which has been used to develop treatments for herpes and toenail fungus. The Michigan Nanotechnology Institute for Medicine and Biological Sciences was established at U-M in 2005 to develop and market medical and biological applications of nanotechnology. Patent applications for the nanoemulsion technology have been filed and exclusively licensed to NanoBio Corporation, an Ann Arbor, Mich.-based biotechnology company in which Baker has a financial interest.
University of Michigan Health System
Anthrax Current Events and Anthrax News RSSBetter immune defense against anthrax
Scientists discover a gene in anthrax-causing bacteria may help defend against this form of bio-warfare.
Argonne researchers develop method that aims to stabilize antibodies
Researchers at the U.S. Department of Energy's Argonne National Laboratory have developed a systematic method to improve the stability of antibodies.
Early detection and quick response are key to defense against anthrax attack
A large attack on a major metropolitan area with airborne anthrax could affect more than a million people, necessitating their treatment with powerful antibiotics.
Data published in the New England Journal of Medicine support use of raxibacumab (ABthrax) for the treatment of inhalation anthrax
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication by the New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company's human monoclonal antibody drug raxibacumab.
One secret to how TB sticks with you
Mycobacterium tuberculosis is arguably the world's most successful infectious agent because it knows how to avoid elimination by slowing its own growth to a crawl.
Unexpected discovery can open a new chapter in the fight against tuberculosis
A close relative of the microorganism that causes tuberculosis in humans has been found to form spores.
Genetic switch potential key to new class of antibiotics
Researchers have determined the structure of a key genetic mechanism at work in bacteria, including some that are deadly to humans, in an important step toward the design of a new class of antibiotics.
UI chemists' DNA biosynthesis discovery could lead to better antibiotics
Combating several human pathogens, including some biological warfare agents, may one day become a bit easier thanks to research reported by a University of Iowa chemist and his colleagues in the April 16 issue of the journal Nature.
Scientists discover new chemical reaction for DNA production in bacteria and viruses
A team of researchers has discovered a new chemical reaction for producing one of the four nucleotides, or building blocks, needed to build DNA.
OHSU scientists partner with others to form center aimed at combating infectious diseases
Oregon Health & Science University and the University of Washington, along with a number of partner institutions across the Northwest, have received federal funding to form a regional research center aimed at combating emerging or re-emerging infectious diseases that pose a serious threat to human health.
More Anthrax Current Events and Anthrax News Articles
 |
Among the Living by Anthrax If Metallica and Slayer invented speed metal, Anthrax brought it to the East Coast and imbued it with the attitude and excitement of New York hardcore. Among the Living is, without a doubt, their finest hour--a roaring, adrenaline-pumped collection of flailing beats, precise, razor-edged riffs and shout-along refrains. Unlike most full-throttle metal vocalists of the era, Joey Belladonna chose to sing as well as shout, giving songs like "Among the Living," "Indians" and "Efilnikcufecin" ("nice fuckin' life" spelled backwards) a decided melodic edge. Yet Scott Ian and Dan Spitz's buzzsaw guitar flurries, and Charlie Benante's insistent drumming, prevented the songs from ever degenerating into the run-of-the-mill heavy metal they so despised. --Jon Wiederhorn |
 |
Spreading the Disease by Anthrax |
![Among The Living [Explicit]](http://ecx.images-amazon.com/images/I/51ZprdREUQL._SL160_.jpg) |
Among The Living [Explicit] Anthrax (Primary Contributor) |
 |
Among the Living by Anthrax Pioneering metal band Anthrax, one of the genre's most influential, innovative and respected groups, melded the speed and fury of hardcore punk with the guitars and vocals of heavy metal to help create speed and thrash metal. Now what many consider the group's greatest album, 1987's "Among The Living," has been expanded with bonus tracks and a concert DVD, and digitally remastered for the first time, for the CD+DVD package AMONG THE LIVING (DELUXE EDITION) "Among The Living," originally produced by Eddie Kramer and Anthrax, was the band's third full-length album and featured the lineup of singer Joe Belladonna, lead guitarist Dan Spitz, rhythm guitarist Scott Ian, bassist Frank Bello and drummer Charlie Benante. Building on an underground following with signature tracks such as "I... |
 |
Persistence of Time by Anthrax |
|
Bring The Noise Anthrax (Primary Contributor) | |
 |
State of Euphoria by Anthrax |
 |
We've Come for You All by Anthrax You'll find no rap metal or nu metal on We've Come for You All--just Anthrax's inimitable thrash-metal melded with contemporary melodies, dynamics, and booming, arena-worthy production. Two way-cool guests--Roger Daltrey and Pantera guitarist Dimebag Darrell--are under-utilized on their respective songs, but with machine-gun, heart-pounding double-bass drums and vocalist John Bush's convincing snarl, it hardly matters. Bush, who has been in Anthrax since the early '90s, has been part of much of the group's best and most mature (if not most commercially successful) material. The dynamic "Superhero" is a winner, as is the radio-ready, not-too-heavy "Safe Home." "Nobody Knows Anything" and "Strap It On" are the best of the heaviest entries. Effective acoustic moments, Scott Ian's guitar... |
 |
Anthrax: Anthrology: No Hit Wonders 1985-1991 by Anthrax |
 |
Sound of White Noise - Expanded Edition Anthrax (Primary Contributor) |
| © 2009 BrightSurf.com |